Denosumab-话题@MedSci

#Denosumab#

11篇内容 | 1492人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2253969, encodeId=3d4c225396958, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a> <a href='/topic/show?id=8d95109e27ef' target=_blank style='color:#2F92EE;'>#系统性红斑狼疮(SLE)#</a>, objectTitle=Lupus Sci Med：Denosumab治疗系统性红斑狼疮合并骨质疏松的疗效及影响因素分析, objectType=article, longId=865087, objectId=434686508ec1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719494105549_2570354.jpg, objectUrl=/article/show_article.do?id=434686508ec1, replyNumber=0, likeNumber=10, createdTime=2025-02-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=434686508ec1, moduleTitle=Lupus Sci Med：Denosumab治疗系统性红斑狼疮合并骨质疏松的疗效及影响因素分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=434686508ec1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2187259, encodeId=60a3218e259c5, content=<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a> <a href='/topic/show?id=0775101884f0' target=_blank style='color:#2F92EE;'>#骨转移#</a> <a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a> <a href='/topic/show?id=972411116460' target=_blank style='color:#2F92EE;'>#MW032#</a>, objectTitle=JAMA ONCOLOGY：实体瘤相关骨转移治疗新选择：MW032与Denosumab（地诺单抗）效用和安全性的对照分析, objectType=article, longId=813276, objectId=34f68132e640, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/patient-meeting-a-doctor-PAYSRMZ.jpg, objectUrl=/article/show_article.do?id=34f68132e640, replyNumber=0, likeNumber=142, createdTime=2024-02-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=34f68132e640, moduleTitle=JAMA ONCOLOGY：实体瘤相关骨转移治疗新选择：MW032与Denosumab（地诺单抗）效用和安全性的对照分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34f68132e640)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1517145, encodeId=9913151e145cc, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=ASCO：Denosumab辅助治疗乳腺癌的长期预后, objectType=article, longId=728244, objectId=9c3ce282447f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3ce282447f, replyNumber=0, likeNumber=84, createdTime=2022-06-01, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3ce282447f, moduleTitle=ASCO：Denosumab辅助治疗乳腺癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3ce282447f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517144, encodeId=d3bd151e1441e, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, objectType=article, longId=203277, objectId=fdc22032e7e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdc22032e7e0, replyNumber=0, likeNumber=76, createdTime=2020-11-13, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdc22032e7e0, moduleTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdc22032e7e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517143, encodeId=e013151e143cf, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=Lancet Oncol：Denosumab对早期乳腺癌患者骨转移的影响, objectType=article, longId=184114, objectId=ffed184114fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffed184114fe, replyNumber=0, likeNumber=78, createdTime=2019-12-05, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffed184114fe, moduleTitle=Lancet Oncol：Denosumab对早期乳腺癌患者骨转移的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffed184114fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517142, encodeId=1b2a151e14262, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=Lancet Oncol：Denosumab治疗骨巨细胞瘤, objectType=article, longId=182590, objectId=db251825901e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db251825901e, replyNumber=0, likeNumber=73, createdTime=2019-11-09, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db251825901e, moduleTitle=Lancet Oncol：Denosumab治疗骨巨细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db251825901e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517141, encodeId=b4e4151e14162, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=J Clin Med：Denosumab治疗骨质疏松症骨质疏松症的疗效和安全性, objectType=article, longId=160285, objectId=69931602858e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69931602858e, replyNumber=0, likeNumber=85, createdTime=2019-02-19, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69931602858e, moduleTitle=J Clin Med：Denosumab治疗骨质疏松症骨质疏松症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69931602858e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517140, encodeId=9abf151e1407a, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=Hematology：Denosumab对输血依赖性地中海贫血和骨质疏松症患者血清骨形态发生蛋白拮抗剂noggin的影响, objectType=article, longId=158923, objectId=ebd9158923fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebd9158923fd, replyNumber=0, likeNumber=74, createdTime=2019-01-27, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebd9158923fd, moduleTitle=Hematology：Denosumab对输血依赖性地中海贫血和骨质疏松症患者血清骨形态发生蛋白拮抗剂noggin的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebd9158923fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517139, encodeId=5a35151e139e1, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=FDA批准Denosumab用于糖皮质激素诱导的骨质疏松症, objectType=article, longId=138882, objectId=329f13888260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=329f13888260, replyNumber=0, likeNumber=88, createdTime=2018-05-24, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=329f13888260, moduleTitle=FDA批准Denosumab用于糖皮质激素诱导的骨质疏松症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=329f13888260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517138, encodeId=dea8151e1382c, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者, objectType=article, longId=136728, objectId=2a86136e2899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a86136e2899, replyNumber=0, likeNumber=114, createdTime=2018-04-29, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a86136e2899, moduleTitle=Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a86136e2899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517137, encodeId=5061151e137ca, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=WCO会议：Denosumab的长期使用能够降低绝经后骨质疏松症患者的骨折发生率, objectType=article, longId=136478, objectId=bc951364e8ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc951364e8ab, replyNumber=0, likeNumber=87, createdTime=2018-04-27, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc951364e8ab, moduleTitle=WCO会议：Denosumab的长期使用能够降低绝经后骨质疏松症患者的骨折发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc951364e8ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517136, encodeId=a4e8151e13640, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=EUR J Cancer：denosumab时代下的骨巨细胞瘤, objectType=article, longId=125003, objectId=e0271250030e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0271250030e, replyNumber=0, likeNumber=72, createdTime=2017-12-30, rootId=0, userName=ms3297076796458174, userId=974011042918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0271250030e, moduleTitle=EUR J Cancer：denosumab时代下的骨巨细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0271250030e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517135, encodeId=2f9f151e1354c, content=<a href='/topic/show?id=f8975849b7' target=_blank style='color:#2F92EE;'>#Denosumab#</a>, objectTitle=EUR J Cancer：Denosumab用于晚期/不可切除的骨巨细胞瘤（GCTB）：未来的路要走多久？, objectType=article, longId=124995, objectId=c98d12499593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c98d12499593, replyNumber=0, likeNumber=76, createdTime=2017-12-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c98d12499593, moduleTitle=EUR J Cancer：Denosumab用于晚期/不可切除的骨巨细胞瘤（GCTB）：未来的路要走多久？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c98d12499593)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Denosumab

2020-05-29

梅斯管理员

#Denosumab# #系统性红斑狼疮(SLE)#

Lupus Sci Med：Denosumab治疗系统性红斑狼疮合并骨质疏松的疗效及影响因素分析

2025-02-28发表于陕西省

梅斯管理员

#实体瘤# #骨转移# #Denosumab# #MW032#

JAMA ONCOLOGY：实体瘤相关骨转移治疗新选择：MW032与Denosumab（地诺单抗）效用和安全性的对照分析

2024-02-14发表于陕西省

ms3297076796458174

#Denosumab#

ASCO：Denosumab辅助治疗乳腺癌的长期预后

2022-06-01

ms3297076796458174

#Denosumab#

韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验

2020-11-13

zhouqu_8

#Denosumab#

Lancet Oncol：Denosumab对早期乳腺癌患者骨转移的影响

2019-12-05

ms3297076796458174

#Denosumab#

Lancet Oncol：Denosumab治疗骨巨细胞瘤

2019-11-09

ms3297076796458174

#Denosumab#

J Clin Med：Denosumab治疗骨质疏松症骨质疏松症的疗效和安全性

2019-02-19

ms3297076796458174

#Denosumab#

Hematology：Denosumab对输血依赖性地中海贫血和骨质疏松症患者血清骨形态发生蛋白拮抗剂noggin的影响

2019-01-27

ms3297076796458174

#Denosumab#

FDA批准Denosumab用于糖皮质激素诱导的骨质疏松症

2018-05-24

ms3297076796458174

#Denosumab#

Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者

2018-04-29

ms3297076796458174

#Denosumab#

WCO会议：Denosumab的长期使用能够降低绝经后骨质疏松症患者的骨折发生率

2018-04-27

ms3297076796458174

#Denosumab#

EUR J Cancer：denosumab时代下的骨巨细胞瘤

2017-12-30

zhaojie88

#Denosumab#

EUR J Cancer：Denosumab用于晚期/不可切除的骨巨细胞瘤（GCTB）：未来的路要走多久？

2017-12-30